|
Volumn 26, Issue 6, 2011, Pages 426-429
|
Insulin pens vs. vials and syringes: Differences in clinical and economic outcomes
|
Author keywords
Diabetes; Insulin; Insulin pen; Medicationdosing devices
|
Indexed keywords
BIPHASIC INSULIN;
HUMAN INSULIN;
INSULIN;
INSULIN ASPART;
INSULIN DERIVATIVE;
INSULIN DETEMIR;
INSULIN GLARGINE;
INSULIN GLULISINE;
INSULIN LISPRO;
ISOPHANE INSULIN;
RECOMBINANT HUMAN INSULIN;
ANTIDIABETIC AGENT;
CONTAINER;
COST CONTROL;
COST UTILITY ANALYSIS;
DIABETES MELLITUS;
DRUG DELIVERY SYSTEM;
HEALTH CARE COST;
HUMAN;
HYPOGLYCEMIA;
INSULIN PEN;
INSULIN TREATMENT;
MEDICAL DECISION MAKING;
PATIENT COMPLIANCE;
PATIENT PREFERENCE;
PATIENT SATISFACTION;
PHARMACIST;
RISK REDUCTION;
SHORT SURVEY;
SYRINGE;
TREATMENT OUTCOME;
VIAL;
ECONOMICS;
DIABETES MELLITUS;
HEALTH CARE COSTS;
HUMANS;
HYPOGLYCEMIC AGENTS;
INSULIN;
SYRINGES;
TREATMENT OUTCOME;
|
EID: 80051559278
PISSN: 08885109
EISSN: None
Source Type: Journal
DOI: 10.4140/TCP.n.2011.426 Document Type: Short Survey |
Times cited : (8)
|
References (7)
|